Pancreatic Cancer Research

ResearcherXinjiang Medical UniversityActive in the last 2 years

Rexiati Ruze

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0891-5307; OpenAlex author ID A5067680016. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2021: 2 papers · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 11

  1. The early-onset pancreatic cancer paradox: a systematic review and meta-analysis. Co-author DOI 10.1093/jnci/djag373↗
  2. Enhanced cytokine signaling and ferroptosis defense interplay initiates obesity-associated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217162↗
  3. Immune-related signature identifies IL1R2 as an immunological and prognostic biomarker in pancreatic cancer. Co-author DOI 10.1097/jp9.0000000000000175↗
  4. SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signaling pathway. Co-author DOI 10.1038/s41419-023-05987-7↗
  5. Cell-in-Cell-Mediated Entosis Reveals a Progressive Mechanism in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.08.035↗
  6. Lipid metabolism in pancreatic cancer: emerging roles and potential targets. Co-author DOI 10.1002/cac2.12360↗
  7. Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. Co-author DOI 10.1186/s12885-022-09927-0↗
  8. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in … First author DOI 10.1186/s12885-022-09983-6↗
  9. Prognostic value of glycolysis markers in pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.3389/fonc.2022.1004850↗
  10. Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. Co-author DOI 10.1186/s12935-021-01928-6↗
  11. S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2021.758004↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianlu Song · 10 shared papers, 2021–2024 · strength 1.81
  2. Ruiyuan Xu · 10 shared papers, 2021–2024 · strength 1.81
  3. Xinpeng Yin · 8 shared papers, 2022–2024 · strength 1.52
  4. Yupei Zhao · 8 shared papers, 2021–2024 · strength 1.47
  5. Yuan Chen · 8 shared papers, 2021–2024 · strength 1.44
  6. Chengcheng Wang · 4 shared papers, 2021–2024 · strength 0.70
  7. Qiang Xu · 3 shared papers, 2022 · strength 0.50
  8. Chengcheng Wang · 2 shared papers, 2023–2024 · strength 0.43
  9. Chengcheng Wang · 2 shared papers, 2022–2023 · strength 0.35
  10. Tuerganaili Aji · 1 shared paper, 2026 · strength 0.27
  11. Hui Zhang · 1 shared paper, 2023 · strength 0.18
  12. Qiang Xu · 1 shared paper, 2022 · strength 0.17
  13. Chengcheng Wang · 1 shared paper, 2021 · strength 0.16
  14. Jinshou Yang · 1 shared paper, 2021 · strength 0.13
  15. Lei You · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.